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Abstract
Objective: Both soluble endothelial protein C receptor (sEPCR) and factor VIII (FVIII) seem to be poten-
tial mediators in thrombotic and inflammatory states. The aim of the present study was to determine the 
relation between plasma sEPCR and FVIII levels in a group of healthy Turkish infants.
Materials and Methods: The study population consisted of 50 healthy infants aged 6 months (Group 1, 
n=23) and 12 months (Group 2, n=27) having no acute or chronic infection and/or disease. sEPCR 
levels and FVIII levels were measured by ELISA and one stage factor assay method, respectively.
Results: The sEPCR levels of the infants aged 6 months were found higher than those of the infants aged 
12 months (p<0.001). There was a correlation between sEPCR and FVIII levels of the infants in Group 
1 (6-month-old infants) (r=0.678, p<0.001). FVIII/sEPCR index was 0.73±0.3 and 1.0±0.5 in Group 1 
and Group 2, respectively (p=0.027). A correlation between infant age and FVIII/sEPCR index was 
found (r=0.312, p=0.027). 
Conclusion: The FVIII/sEPCR index in healthy infants reflects the physiological condition of this popula-
tion. The finding showing a positive relationship between sEPCR and FVIII levels suggests a possible 
interaction between these mediators in healthy infants aged six months. (Turk J Hematol 2011; 28: 27-32)
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Özet
Amaç: Çözünür endotelyal protein C reseptörü (sEPCR) ve faktör VIII (FVIII) trombotik ve inflamatuvar 
durumlarda potansiyel arabileşenler olarak görülmektedir. Bu çalışmanın amacı; bir grup sağlıklı süt çocu-
ğunda plazma sEPCR ve FVIII düzeyleri arasındaki ilişkiyi tanımlamaktır.  
Yöntem ve Gereçler: Çalışma grubunu herhangi bir akut ya da kronik hastalığı ve/veya enfeksiyonu olma-
yan, sağlıklı 6 aylık (Grup 1, n=23) ve 12 aylık (Grup 2, n=27) çocuklar oluşturmaktadır. sEPCR düzeyle-
ri ve FVIII düzeyleri sırasıyla; ELISA ve one stage factor metodu ile çalışılmıştır. 
Bulgular: Altı aylık çocukların sEPCR düzeyleri oniki aylık olanlardan daha yüksek bulunmuştur (p<0.001). 
Grup 1’i oluşturan 6 aylık çocuklarda sEPCR ve FVIII düzeyleri arasında bir korelasyon vardır (r=0.678, Introduction
The protein C anticoagulant pathway is critical to 
both regulation of the blood coagulation process 
and control of the innate inflammatory response 
and some of its associated downstream pathologies 
[1,2]. The endothelial protein C receptor (EPCR) 
plays an important role in this pathway [3]. EPCR is 
preferentially expressed by endothelial cells of large 
blood vessels and increases the rate of protein C 
activation by the thrombin/thrombomodulin com-
plex  [3,4]. Increased levels of a soluble form of 
EPCR (sEPCR) in plasma lead to dysfunction of the 
EPCR-mediated coagulation [5]. sEPCR levels 
increase in conditions associated with considerable 
thrombin production such as vasculitis, sepsis and 
systemic lupus erythematosus [6,7]. 
Factor VIII (FVIII) is a plasma glycoprotein in the 
coagulation cascade, and it is the cofactor of factor 
IXa in the activation of factor X. FVIIIa can be inac-
tivated by activated protein C [1,2]. Previous studies 
have shown that the coagulant activity of FVIII is 
increased as an acute phase reaction in thrombosis 
[8,9]. Elevated plasma levels of FVIII are associated 
with an increased risk of venous and arterial throm-
bosis [10,11]. Possible mechanisms thought to be 
associated with elevated FVIII are the enhancement 
of thrombin formation or the induction of acquired 
activated protein C resistance, but the molecular 
mechanisms that underlie elevated FVIII are still not 
clear. 
Although in vivo physiological mechanisms and 
their importance are still unknown, both EPCR and 
FVIIII seem to be potential mediators in thrombotic 
and inflammatory states because of their roles in 
the protein C anticoagulant pathway. Thus, the 
determination of the association between sEPCR 
and FVIII may provide new knowledge about the 
pathogenesis of thrombotic and inflammatory con-
ditions. The aim of this study, therefore, was to 
determine the relation between plasma sEPCR and 
FVIII levels in a group of healthy Turkish infants. 
Materials and Methods 
This study was conducted at the Department of 
Pediatrics, Divisions of Pediatric Molecular Genetics 
and Social Pediatrics. Ethics approval was obtained 
from the Ethics Committee of the School of Medicine. 
The study population consisted of healthy infants 
aged 6 and 12 months who were admitted for well-
child visits. They had no acute or chronic infection 
and/or disease. The written informed consent to par-
ticipate was obtained from the parents of all subjects. 
Peripheral blood samples were collected from 
the subjects into tubes containing 1 ml 0.109 M tri-
sodium citrate. Plasma was obtained by centrifuga-
tion at 2500xg for 10 minutes (min) at room tem-
perature. Plasma specimens obtained were main-
tained until the date of measurement at 20±5˚C for 
4 hours (h), at 2-8˚C for 24 h, and at -20˚C for 1 
month. Soluble EPCR levels were determined in 
plasma by using sEPCR Asserachrom enzyme-
linked immunosorbent assay (ELISA) kits from 
Diagnostica Stago (Asnières, France), according to 
the manufacturer’s instructions. Factor VIII levels 
were measured concomitantly with one stage fac-
tor assay method and FVIII-absent plasma (Sigma 
Diagnostica Inc, St. Louis, MO).
Statistical analysis
Statistical analysis was performed using the SPSS 
11.5. Descriptive analysis summarizing the charac-
teristics and the levels of sEPCR and FVIII is pre-
sented. Since the plasma sEPCR and FVIII measure-
ments were not normally distributed, nonparamet-
ric tests were conducted to compare these param-
eters. The Mann-Whitney U test was used to com-
pare sEPCR and FVIII levels between the groups. 
Nonparametric correlations between sEPCR and 
FVIII levels were evaluated using the Spearman cor-
relation test. FVIII/sEPCR index was calculated in 
the groups. The Student t test was used to compare 
FVIII/sEPCR index between the groups, and the 
Pearson correlation test was used to evaluate the 
correlation between this index and age. 
p<0.001). FVIII/sEPCR indeksi Grup 1’de 0.73±0.3 ve Grup 2’de 1.0±0.5 olarak bulunmuştur (p=0.027). 
Çocuğun yaşı ve FVIII/sEPCR indeksi arasında bir korelasyon saptanmıştır (r=0.312, p=0.027).  
Sonuç: Çalışmada sağlıklı çocuklarda kullanılan FVIII/sEPCR indeksi bu populasyonun fizyolojik durumunu 
yansıtmaktadır. Altı aylık çocuklarda sEPCR ile FVIII arasındaki pozitif ilişki bu yaş grubundaki çocuklarda 
bu mediatörler arasında muhtemel bir etkileşim olduğunu gösterebilir.  (Turk J Hematol 2011; 28: 27-32)
Anahtar kelimeler: sEPCR, Factor VIII, sağlıklı süt çocukları, tromboz
Geliş tarihi: 1 Mart 2010     Kabul tarihi: 29 Haziran 2010 
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Totally, 50 healthy infants were studied. These 
infants were divided into two groups according to 
age. Group 1 consisted of 23 infants aged 6 months 
(9 boys and 14 girls), and Group 2 consisted of 27 
infants aged 12 months (13 boys and 14 girls). 
Table 1 shows the sEPCR and FVIII levels of the 
infants. There was a significant difference between 
Group 1 and Group 2 with respect to sEPCR levels 
(p<0.001), with the sEPCR levels of infants aged 6 
months found to be significantly higher than those 
of the infants aged 12 months. There was no differ-
ence between the groups with respect to the FVIII 
levels. Concerning all infants and groups, there was 
no statistical difference between boys and girls in 
sEPCR or FVIII levels. 
In the correlation analysis, there was a correla-
tion between sEPCR and FVIII levels of the infants 
in Group 1 (aged 6 months) (r=0.678, p<0.001) 
(Figure 1). However, no correlation was present 
between the sEPCR and FVIII levels in Group 2 
(aged 12 months) (r=-0.251, p=0.206). 
With respect to all infants, the mean FVIII/sEPCR 
index was found as 0.88 (median: 0.85, SE: 0.06, min: 
0.3, max: 3.1). There was a statistically significant dif-
ference in the FVIII/sEPCR index between the groups 
(p=0.027; 0.73±0.3 and 1.0±0.5 for Group 1 and 
Group 2, respectively). In the correlation analysis, 
there was a correlation between the infant age and 
the FVIII/sEPCR index (r=0.312, p=0.027).
Discussion
This is the first study in the literature to examine 
the relationship between plasma sEPCR and FVIII 
levels in healthy infants as an indicator of the physi-
ological condition.  This study also highlights the 
Figure 1. The correlations between sEPCR levels and FVIII levels according to groups
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Table 1. sEPCR and FVIII concentrations according to groups 
   All infants   Group 1  Group 2
   (n=50)  (n=23)  (n=27)
sEPCR (ng/ml)       
  Mean ± SE 145.4±10.7  175.1±17.9  120.0±10.8
  Median 112.0  130.0  102.0
  Min-Max 67.0-346.0  95.0-346.0  67.0-280.0
  95% CI1 123.8-166.9  137.9-212.3  97.8-142.3
                            P*                                                       <0.001
FVIII (U/dl)  Mean ± SE 109.6±6.2  116.1±11.8  104.1±5.4
  Median 100.5  103.9  96.6
  Min-Max 42.0-284.0  42.0-284.0  72.0-209.0
  95% CI1 97.2-122.0  91.6-140.6  92.9-115.2
                            P*                                                       >0.05
195% CI: Confidence intervals, * Mann-Whitney U test 
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index. 
Protein C activation is regulated by numerous 
mediators in the coagulation process, and activated 
protein C has a variety of anti-inflammatory activi-
ties [1]. Increased levels of sEPCR in plasma lead to 
dysfunction of the EPCR-mediated coagulation [5]. 
sEPCR levels vary among healthy subjects, and the 
bimodal distribution has been reported several 
times [12-14]. A recent study showed a negative 
relationship between sEPCR levels and an individu-
al’s age; that is, sEPCR levels of healthy children 
were found to be higher than those of healthy adults 
(14). The levels of sEPCR and FVIII reflect the phys-
iological condition of these mediators in this healthy 
population; however, the physiological importance 
and influence of sEPCR levels in vivo and the rela-
tion to FVIII are unknown. 
Increased plasma sEPCR levels were found asso-
ciated with an increased risk of venous thrombosis 
and thrombin generation [12,15]. Further, it was 
reported that increased FVIII levels are an important 
risk factor for venous and arterial thrombosis [11,16]. 
Yürürer et al. [17] showed a negative relationship 
between sEPCR and FVIII levels in a group of pedi-
atric stroke patients. They suggested that this asso-
ciation makes each of them regulate the action of 
the other, and may play a role in the stroke patho-
physiology. Under the physiological circumstances, 
we found that the sEPCR levels of infants aged 6 
months were significantly higher than of infants 
aged 12 months. We also found a positive relation-
ship between sEPCR and FVIII levels in the 6-month-
old healthy infants, but not in the 12-month-old 
infants. These findings, which indicate the physio-
logical state in healthy infants, may reflect the inter-
actions among the mediators in the coagulation 
system over the first months of life. Thrombin is a 
multifunctional serine protease generated at the 
site of vascular injury and has a key role in blood 
coagulation. Cellular effects of thrombin are medi-
ated by protease-activated receptors (PARs), mem-
bers of the G protein-coupled receptors. Their 
expression is low in contractile vascular smooth 
muscle cells (SMC), but becomes markedly up-
regulated upon injury [18]. We suggest that the 
overexpression of PARs or the presence of unknown 
mechanisms during the early stage of life may play 
a role in the tendency towards thrombotic condi-
tions. We may speculate that the positive relation 
between sEPCR and FVIII levels in 6-month-old 
infants may be associated with the enhancement of 
thrombin formation and probably with the overex-
pression of PARs. Further studies are needed to 
evaluate the associations among the mediators in 
the coagulation system in a variety of healthy 
groups, including newborns, infants, children, and 
adults, under physiological circumstances. 
As the first in the literature, we proposed the ratio 
of FVIII/sEPCR as an index of the physiological sta-
tus of the coagulation system. We found a correla-
tion between infant age and the FVIII/sEPCR index 
in this healthy group. In our study population, this 
index reflects the physiological conditions regarding 
the coagulation pathway process under normal 
conditions. Although the in vivo importance of this 
index is unknown, determining the difference in 
this index between physiological and pathological 
conditions may confirm the potential interactions 
between the mediators in the coagulation process. 
We consider the possibility of using this index in 
further studies in pathologic states in which the 
pathogenesis involves thrombotic and inflammato-
ry processes. 
In this study, we aimed primarily to determine 
the actual physiological condition in healthy infants. 
Because of the potential tendency to thrombotic 
states over the first months of life and the possible 
risk of complexity in our findings, the younger 
infants were not included in the study. On the other 
hand, the interactions among the mediators in the 
coagulation system over the first month of life need 
to be determined, in order to clarify the detailed 
mechanisms under the tendency of thrombosis. 
Therefore, further studies with the aim of assessing 
the relations among the mediators, such as EPCR, 
FVIII, other factors, PARs, or other receptors, may be 
conducted in healthy infants in the first month of 
life. 
Various genetic and environmental conditions 
have been discussed as risk factors for thrombotic 
events in adult and pediatric patients [19]. 
Functional polymorphisms in the EPCR gene may 
increase/decrease the risk of thrombosis, espe-
cially in carriers of prothrombotic mutations [20]. 
Familial clustering of high factor VIII levels in 
patients with venous and arterial thromboembo-
lism and retinal artery occlusion were reported in 
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pointed to genetic influences on these mediator 
levels. It is conceivable that the genetic polymor-
phisms of the FVIII and/or EPCR genes are linked 
with high FVIII and/or sEPCR levels in patients with 
thrombosis. The evaluation of these polymor-
phisms may be an important clinical indicator for 
determination of the thrombosis risk in a healthy 
population. In a recent study, Ay et al. [24] found 
no evidence of an association between observed 
single nucleotide polymorphisms in exons of the 
FVIII gene and high thrombosis levels. The findings 
in the literature seem to be contradictory about the 
polymorphisms in the genes of the mediators 
regarding the protein C system; therefore, further 
detailed studies are needed to assess these poly-
morphisms to determine their roles in the patho-
genesis of thrombosis. 
In conclusion, this is the first study in the litera-
ture to examine the relationship between plasma 
sEPCR and FVIII levels in healthy infants and also to 
determine the ratio of FVIII/sEPCR as an index. Both 
sEPCR and FVIIII seem to be potential mediators in 
thrombotic and inflammatory states. The levels of 
sEPCR and FVIII in our study group reflect the phys-
iological levels in this healthy population. We found 
a positive relationship between sEPCR and FVIII 
levels in 6-month-old healthy infants, but not in 
12-month-old infants. This may reflect the interac-
tions among the mediators in the coagulation sys-
tem over the first months of life under physiological 
circumstances. We also found a correlation between 
infant age and the FVIII/sEPCR index in this healthy 
group. Although the in vivo importance of this index 
is unknown, we consider the possibility of using this 
index in further studies in pathologic states in which 
the pathogenesis involves thrombotic and inflam-
matory processes. On the other hand, future studies 
are needed to evaluate the physiological associa-
tions among the mediators, such as sEPCR and 
FVIII, in the coagulation system in a variety of 
healthy groups, including newborns, infants, chil-
dren, and adults. 
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